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Abstract
Fibronectin is a matrix glycoprotein which has not only been found to be over-expressed in several
cancers, but has been shown to participate in several steps of tumorigenesis. The purpose of this
review is to illustrate how aberrant fibronectin expression influences tumor growth, invasion,
metastasis and therapy resistance. In particular, this review will focus on the interactions between
cell receptor ligands and fibronectin and how this interaction influences downstream signaling
events that aid tumor progression. This review will further discuss the possible implications of
therapeutic drugs directed against fibronectin and/or cellular interactions with fibronectin and will
additionally discuss novel approaches by which to limit intra- and extra-tumoral fibronectin
expression and the cellular events which lead to aberrant fibronectin expression. It is anticipated
that these studies will set a basis for future research that will not only aid understanding of
fibronectin and its prognostic significance, but will further elucidate novel targets for therapeutics.
Key words: Fibronectin, extracellular matrix, integrins, tumorigenesis, metastasis, therapy resistance.

Introduction
The extracellular matrix (ECM) is a protein rich
entity which supports tissue structure, cell adhesion,
cell-cell communication and differentiation [1].
Numerous studies have found that ECM proteins are
aberrantly expressed in carcinomas and actively
participate in tumor progression. In particular,
fibronectin is receiving increasing interest as a result
of its participation in multiple stages of tumor
progression.
Under
homeostatic
conditions,
fibronectin has been shown to play a role in cell
growth, differentiation, migration, and is additionally
involved in processes such as wound healing and
blood coagulation [2]. With regard to cancer,
fibronectin is not only increased in tumors where its
altered expression has been shown to promote tumor
growth [3-5], migration [6, 7] and invasion [8, 9] but
fibronectin has also been reported to limit tumor cell
responsiveness to therapy [10-12] (Figure 1).

Fibronectin has even been shown to alter mammary
epithelial cell behavior. For instance, the introduction
of fibronectin to differentiated mammary epithelial
cell acini cultured atop the basement membrane
extract Matrigel caused the cells to re-enter the cell
cycle thus reversing their growth arrest and acinar
morphology [13]. Work in our lab has shown that loss
of caveolin-1, the main structural protein of caveolae,
results in increased expression of fibronectin,
tenascin-C and collagen in murine mammary glands
(Thompson et al, unpublished data). The altered ECM
is accompanied by changes in mammary gland
architecture characterized by increased numbers of
ducts that possess a larger circumference and area
when compared to wild type controls, a result which
may be in part related to increased fibronectin
expression observed in the stroma (Thompson et al,
unpublished data).
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Figure 1: Fibronectin signaling in healthy and tumorigenic cells. In a healthy cell, fibronectin participates in the maintenance of homeostasis. Under
pathological conditions, fibronectin is upregulated and associates with several integrin receptors, resulting in activation of various signaling cascades which ultimately
promote tumorigenesis, metastasis and therapy resistance.

The purpose of this review is to illustrate the
mechanisms in which aberrant fibronectin expression
influences tumorigenesis and therapy resistance. In
particular, this review will focus on the interactions
between cell receptor ligands and fibronectin and
how this interaction influences downstream signaling
events that facilitate tumor progression. Further, this
review will highlight potential strategies whereby
fibronectin deposition, engagement with cell surface
receptors and activation of cell signaling pathways
may be exploited to halt tumor progression. In this
manner, it is with anticipation that a new generation
of novel therapeutics may be developed to better
combat fibronectin’s participation in tumorigenesis.

Tumor Progression
Fibronectin has been shown to play a central role
in processes associated with tumor progression. In
particular, α5β1 integrin and fibronectin have not only
been shown to be upregulated in tumors, but have
also been reported to participate in tumor cell
proliferation. For example, Nam et al found that
fibronectin and the extra domain (ED)-A splice
variant of fibronectin were associated with higher
α5β1-integrin expression in malignant as opposed to
normal breast epithelial cells cultured atop Matrigel

[5]. Interestingly, the authors also reported that total
fibronectin, ED-A fibronectin and α5β1-integrin was
markedly upregulated in the malignant breast cancer
lines but not in non-malignant breast epithelial cells
[5]. Similarly, Mierke et al also determined that α5β1
integrin was upregulated in MDA-MB-231 breast
cancer cells and further demonstrated that fibronectin
augmented the invasiveness of α5β1 expressing breast
cancer cells cultured atop collagen hydrogels [3]. To
investigate
a
mechanism
responsible
for
α5β1-fibronectin in tumor growth, Mitra et al
examined the activation of the receptor tyrosine
kinase c-Met in human HeyA8 and SKOV3ip ovarian
cancer cell lines following α5β1 engagement with
fibronectin [4]. Results showed that binding of cellular
α5β1 to fibronectin resulted in increased activation of
the c-Met/FAK/Src signaling pathways in ovarian
cancer cells [4]. Blocking ovarian cancer cell α5β1
interaction with fibronectin reduced c-Met mediated
focal adhesion kinase (FAK) and Src phosphorylation
in vitro and in vivo and additionally reduced tumor
weight and proliferation in xenograft tumors [4],
suggesting that α5β1-fibronectin interactions regulate
cell signaling pathways important for ovarian cancer
growth. In an effort to further examine the effects of
integrins on ovarian tumor cell proliferation, Kenny et
http://www.jcancer.org
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al examined adhesion and proliferation of human
ovarian cancer cells following culture atop a
de-cellularized ECM derived from human omental
tumors [8]. When cultured in the presence of antiα5β1, αvβ3 and RGD peptides, the authors observed
decreased adhesion and proliferation of ovarian
cancer cells cultured atop the de-cellularized ECM
supporting a role for fibronectin-integrin engagement
in ovarian cell proliferation [8].
A defining feature of tumors is the ability of
cancer cells to evade apoptosis. In an effort to
delineate a role for fibronectin-integrin interactions on
tumor cell resistance to apoptosis, Han et al used
Wortmannin to block PI3-K in human bronchial
epithelial BEAS-2B and 16-HBE cell lines following
α5β1 cellular engagement with fibronectin [14]. The
authors found that Wortmannin caused an increase in
DNA fragmentation indicative of apoptosis [14]. In
the absence of Wortmannin, fibronectin stimulated
α5β1-mediated phosphorylation of PI3-K and
downstream signaling of PI3-K/Akt, which in turn,
down-regulated p21 and the tumor suppressor gene
p53 and upregulated cyclin D1 in the bronchial
epithelial cells [14].
In addition to integrins, fibronectin binding to
cell surface receptors such as syndecans has been
reported to regulate tumor cell ECM attachment and
growth. This is evidenced by work from Huang et al
who examined the effect of tenascin-C on tumor cell
adhesion to fibronectin [15]. Using MDA-MB-435
breast cancer and T98G gliobastoma cell lines, the
authors found that tenascin-C bound to the FNIII13 of
the HepII site on fibronectin blocked syndecan-4
mediated tumor cell binding to fibronectin [15].
Overexpressing syndecan-4 reversed the effects of
tenascin-C induced inhibition of tumor cell adhesion
to fibronectin, suggesting that tenascin-C bound to the
FNIII13
site
on
fibronectin
disrupts
syndecan-4-fibronectin signaling [15]. Similarly,
syndecan 1 and 4 engagement with fibronectin was
reported to promote MDA-MB-231 breast cancer cell
adhesion and migration on collagen and proliferation
on fibronectin matrices, an observation which was
reversed upon incubation with anti-syndecan 1 and 4
antibodies [16].
Aside from direct cellular interactions with
fibronectin on tumor progression, others have
reported a role for fibronectin in tumor
immunosuppression. For example, Sengupta et al
examined the role of siRNA against fibronectin in
glioma tumor growth and immune cell activation [17].
Using GL261 glioma tumor cells, the authors observed
delayed tumor cell proliferation and growth in mice
injected with fibronectin silenced GL261 cells [17].
This observation was in part, attributed to a reduction
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in the number of T-regulatory cells, which inhibit the
activity of T helper cells.
While the full length form of fibronectin plays an
important role in tumorigenesis, isoforms of
fibronectin, such as the ED-A and ED-B variants, have
been reported to regulate tumor growth. For instance,
Rybak et al demonstrated markedly higher expression
of ED-A fibronectin in the vasculature of murine liver
metastases from F9 teratocarcinoma cells with
minimal expression observed in non-diseased organs,
pointing to a role for ED-A fibronectin in angiogenesis
[18]. Indeed, a later study demonstrated that ED-A
overexpressing colorectal cancer cells exhibited
upregulated expression of the pro-angiogenic
cytokine vascular endothelial growth factor-C
(VEGF-C) and promoted tumor growth and
lymphangiogenesis in mice [19]. To determine a
mechanism responsible for these observations, the
authors report that ED-A upregulation of VEGF-C is
accomplished via ED-A mediated activation of the
PI3K/Akt pathway. Dose dependent reductions in
VEGF-C were observed following cancer cell
treatment with an inhibitor of PI3K [19]. Aside from a
role in angiogenesis, ED-A fibronectin was reported to
be upregulated in patient colorectal tumors, especially
those that were of advanced stage [20]. Investigating
CD133+/CD44+ colorectal tumor cells, a subset of cells
believed to be responsible for colon cancer initiation,
the authors found that these cells expressed higher
levels of the ED-A receptor α9β1 and further
demonstrated that ED-A interaction with α9β1 was
required for tumor cell proliferation [20]. To elucidate
a mechanism responsible for their observations, Ou et
al found that ED-A sustains Wnt/β-catenin signaling,
necessary for the progression of colorectal cancer
cells, via integrin mediated activation of a FAK/ERK
pathway [20]. In a more recent study, ED-A
fibronectin was shown to increase the population of
myeloid derived cells, known to impair immune
responses to cancer cells, from osteoblasts [21]. To
determine whether the absence of fibronectin
impaired myeloid cell numbers and thus tumor
formation, the authors subcutaneously injected
melanoma cells into either a fibronectin knock out
model (cKO) in which fibronectin expression in
differentiating osteoblasts was conditionally deleted
or a wild type animal (WT) and evaluated for tumor
formation [21]. Tumor growth and the presence of
myeloid cells in tumors were reduced in cKO animals
but not in WT animals [21]. Although the authors
don’t attribute these findings to a specific reduction in
the ED-A fibronectin isoform, they go on to
demonstrate that culture of myeloid cells from cKO
animals with ED-A fibronectin resulted in a reduction
of melanoma apoptosis, suggesting that this
http://www.jcancer.org
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pro-tumor effect results from ED-A activation of
myeloid cells [21].
ED-B fibronectin has also been reported to play a
role in angiogenesis where it has been shown to
promote VEGF expression, tube formation and
proliferation of human vascular endothelial cells [22].
Specifically, the authors found that ED-B fibronectin
was upregulated in vascular endothelial cells in
response to high glucose, TGF-β1 and endothelin-1, a
finding which was reversed following administration
of inhibitors to TGF-β1 and endothelin-1 [22]. These
findings would suggest that growth factor signaling is
an important regulator of ED-B fibronectin mediated
vascular morphogenesis [22]. Despite a role in
angiogenesis, ED-B fibronectin expression has been
documented to be more highly expressed in the
stromal and epithelial compartments of colorectal and
breast carcinomas, but not in endothelial cells [23],
suggesting that additional work is needed in order to
fully elucidate the role of ED-B fibronectin in
tumorigenesis. Regardless of its role in tumorigenesis,
ED-B fibronectin has more recently been exploited as
a molecular marker for prostate cancer. Here, Han et al
synthesized a small peptide to target upregulated
ED-B expression in tumor xenografts harboring
human prostate carcinomas, demonstrating that the
peptide bound to ED-B fibronectin produced by the
tumor cells [24]. It’s conceivable that this strategy may
be utilized for both imaging and diagnostic purposes
as well as delivery of therapeutics.
Overall, these studies suggest that fibronectin,
via engagement with several integrin receptors and
interference with immune function, favors tumor cell
survival and proliferation. Additionally, multiple
isoforms of fibronectin also participate in
tumorigenesis, highlighting the importance of
understanding how the different splice variants of
fibronectin not only interact with cell surface
receptors, but how this interaction activates
downstream signaling pathways important for tumor
growth.

Tumor Invasion and Metastasis
While fibronectin appears to play a key
role in multiple facets of tumor progression, it has also
been shown to participate in processes associated
with tumor migration, invasion and metastasis. To
examine the role of fibronectin on tumor cell
migration, Lou et al overexpressed SOX2 to determine
its role in ovarian tumor cell metastasis [6]. Here, the
overexpression of SOX2 upregulated fibronectin gene
expression resulting in increased migration and
invasion of the A2780 human ovarian cancer cell line
in transwell chambers [6]. Downregulation of
fibronectin using siRNA resulted in a reversal of cell
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migration and invasion despite high expression of
SOX2 indicating that SOX2 signals via fibronectin
during tumor cell metastasis [6]. To further explore
the role of fibronectin on tumor cell migration, Wei et
al sought to demonstrate whether nicotine enhanced
the migration of SW480 colorectal cancer cells through
nicotinic-acetylcholine receptor (7-nAChR) mediated
induction of COX-2 [7], reported to regulate EMT [25].
The authors found that inhibiting 7-nAChR and
COX-2 not only limited fibronectin expression, but
also increased E-cadherin expression, reducing SW480
cell migration [7]. In the absence of COX-2 inhibition,
nicotine enhanced colon cancer cell migration via
7-nAChR and COX-2 mediated up-regulation of
fibronectin expression indicating that inhibition of
COX-2 and 7-nAChR reduced migration of colorectal
cancer cells as a result of a reduction in fibronectin
expression [7].
Integrin engagement has been reported to play a
crucial role in fibronectin mediated tumor cell
invasion. A recent study reported an indispensable
role for fibronectin and the α5β1 integrin on the
invasive capabilities of HeyA8 and SKOV3ip1 human
ovarian cancer cell lines [8]. Here, the authors first
showed that 3D co-culture of ovarian cancer cells with
mesothelial cells supported fibronectin expression
from mesothelial cells via activation of a
TGF-βR1/RAC1/SMAD3 signaling pathway, a
phenomenon which was important for cancer cell
adhesion, proliferation and invasion as silencing of
fibronectin reduced these cellular responses [8]. In an
attempt to further elucidate a role for fibronectin in
tumor cell progression, the authors administered
antibodies against α5 and β1 integrins to 3D
co-cultures of ovarian cancer cells and mesothelial
cells and discovered that tumor cell invasion and
proliferation was reduced up to 40% [8]. In-vivo, the
authors found that treatment of mice with antibodies
against α5 and β1 reduced the number of metastases
and tumor weight from orthotopically injected
ovarian cancer cell lines [8]. These results suggest that
ovarian cancer cells stimulate fibronectin expression
from mesothelial cells via a TGF-β pathway and that
tumor cells adhere, proliferate and invade in response
to α5 and β1 integrin engagement with fibronectin. In a
similar study, it was shown that inhibition of α5 and
β1 integrins significantly reduced ovarian tumor cell
adhesion to a 3D model consisting of primary human
mesothelial cells and fibroblasts and additionally
limited the number of metastases in ovarian cancer
xenografts [26]. Downregulation of E-cadherin on
ovarian cancer cells was specifically shown to
augment α5 integrin expression via activation of FAK
and Erk1 [26]. Further, siRNA of E-cadherin was
shown to increase cancer cell adhesion to fibronectin
http://www.jcancer.org
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and invasion in a Matrigel matrix [26], suggesting that
ovarian cancer cell adhesion to fibronectin and
invasion in a 3D matrix are regulated by decreased
E-cadherin mediated α5 integrin expression. In
addition to ovarian cancer, work by others have
shown that MDA-MB-231 breast cancer, T24 bladder
carcinoma, and 786-O renal adenocarcinoma cells
expressing α5β1 integrins exhibited increased invasion
in 3D collagen matrices which had been polymerized
with fibronectin, further highlighting that integrin
engagement with fibronectin supports tumor cell
invasion in 3D [3]. Interestingly, the addition of
soluble fibronectin at the start of the assay reduced
tumor cell invasion in collagen matrices, suggesting
that differences in the polymerization status of
fibronectin may differentially regulate tumor cell
behavior [3]. A role for αvβ3 interaction with
fibronectin has also been reported to participate in
tumor cell invasiveness. For example, 3D matrices of
clotted plasma, reported to play an important role in
tumor metastasis [27], or fibrin, the principal
component of clots, were found to induce
invadopodia, cellular protrusions which participate in
the early stages of cell migration and invasion,
formation from several tumor cell lines [9].
Invadopodia were associated with increased
expression of αvβ3 integrin and fibronectin matrix
formation [9]. Furthermore, it was found that primary
metastatic kidney tumor cells exhibited an increased
expression of invadopodia formation in addition to
fibronectin and αvβ3 integrin which together
upregulated
the
expression
of
the
epithelial-mesenchymal (EMT) transcription factor
Slug [9]. These results would suggest that αvβ3 and
fibronectin promote tumor cell invadopodia
formation via activation of the EMT transcription
factor Slug.
In order to metastasize to distant sites, tumor
cells make use of altered cell signaling pathways and
matrix metalloproteinases (MMPs), which degrade
and remodel the ECM allowing tumor cell migration.
With regard to a role for fibronectin in altered cell
signaling, Balanis et al showed that adhesion of
MDA-MB-231 breast cancer cells to fibronectin
elicited robust STAT3 activation, a result which was
dependent on cellular expression of FAK and the
tyrosine kinase PYK2 [28]. The authors further
demonstrated that administration of fibronectin to
MDA-MB-231 cells cultured atop 3D hydrogels
resulted in cellular outgrowth and a phenotype
previously linked with enhanced metastatic
properties [28]. Inhibition of β1 integrin or the use of a
small inhibitor against STAT3 reversed these findings,
suggesting that in 3D, MDA-MB-231 breast cancer
cells utilize fibronectin-β1 integrin mediated STAT3
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signaling during invasion [28]. To illustrate a
cooperative role of fibronetin and MMPs in tumor
invasion, Meng et al sought to determine whether
A549 lung cancer cell invasion occurred as a result of
fibronectin-induced FAK activation of MMP9 [29].
The authors found that fibronectin stimulated FAK
phosphorylation and Src recruitment, resulting in
activation of downstream targets, ERK1/2 and
PI3K/Akt in A549 cells, promoting invasion and
migration of the cancer cells in transwell chambers
[29]. Inhibition of ERK1/2 and PI3K resulted in a
reduction of migrating and invasive A549 cells as a
result of downregulation of MMP9, implicating a role
for fibronectin-FAK-MMP9 in lung cancer invasion
[29]. Together, these findings not only suggest an
important role for integrin engagement with
fibronectin, but cooperation between fibronectin and
altered cell signaling and MMP expression in
processes associated with tumor invasion and
metastasis.

Therapy Resistance
Chemotherapeutic agents have undoubtedly
contributed to improved survival rates for individuals
with cancer. Despite these successes, tumor cell
resistance to therapies and relapse are still a common
feature of the disease. While a number of factors have
been implicated in chemotherapy resistance,
fibronectin has received interest. In a study by
Pontiggia et al the efficacy of tamoxifen, an estrogen
receptor antagonist, was used to examine how the
microenvironment limits tumor cell sensitivity to
tamoxifen [12]. Here, the authors co-incubated human
and mouse breast tumor cells with fibronectin and
measured tumor cell sensitivity to tamoxifen [12]. The
addition of fibronectin promoted tamoxifen resistance
via fibronectin-mediated activation of β1-integrin
which in turn, stimulated the PI3K/Akt and
MAPK/Erk 1/2 signaling pathways in both tumor
cell lines [12]. Disrupting the interaction between the
β1-integrin and fibronectin reversed the conferred
resistance, leading to drug-induced apoptosis of the
tumor cells [12]. Similarly, Yuan et al found that β1
integrin and fibronectin were markedly increased in
tamoxifen resistant as opposed to tamoxifen sensitive
MCF7 breast cancer cells [30]. The overexpression of
β1 was associated with increased expression of the
epidermal growth factor receptor (EGFR)/ERK
signaling pathway. Inhibition of β1 improved
tamoxifen sensitivity of resistant MCF7 cells and
further reduced cellular migration following culture
in the presence of conditioned media from carcinoma
associated fibroblasts (CAFs) [30]. Interestingly,
culture of tamoxifen resistant MCF7 cells in CAF
conditioned media resulted in enhanced cell
http://www.jcancer.org
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migration due to CAF produced fibronectin, a result
which was diminished following cellular treatment
with the β1 integrin inhibitor [30]. In addition to
tamoxifen, cetuximab, an antibody that inhibits cell
proliferation when bound to the EGFR, has been
reported to have limited efficacy as a result of tumor
cell resistance [10]. For example, A549 human lung
adenocarcinoma cells and H1299 human non-small
cell lung carcinoma cells were reported to have
diminished cell cytotoxicity to cetuximab and
radiation following culture atop fibronectin coated
surfaces [10]. The observed reduction of cytotoxicity
was a result of tumor cell α5β1 integrin engagement
with fibronectin as silencing these integrins restored
tumor cell sensitivity to cetuximab [10]. Interestingly,
cetuximab was also shown to promote increased
fibronectin expression from both tumor cell lines, a
finding which was reported to result from activation
of the p38-MAPK-ATF2 signaling pathway [10].
siRNA silencing of fibronectin improved cytotoxicity
of cetuximab in H1299 and A549 tumor cell lines,
demonstrating that excess fibronectin in combination
with α5β1 integrin engagement with fibronectin
facilitates cetuximab resistance [10]. In a similar study,
changes in tumor cell apoptosis were analyzed
following etoposide treatment of H69 small cell lung
cancer cells which had been cultured in fibronectin
coated dishes [31]. The results showed that tumor cell
α2, α3, α6, and β1 integrin interaction with fibronectin
inhibited
chemotherapy
induced
apoptosis,
evidenced by decreased caspase 3-activity [31]. Using
breast cancer as a model, Spangenberg et al reported
that
inducible
expression
of
the
ERBB2
proto-oncogene in MCF7 breast cancer cells resulted
in upregulated gene expression of α5 and β1 integrins
[32]. The authors found that MCF7 cells exhibited
increased resistance to cisplatin and 5-fluorouracil as
a result of ERBB2 induced α5β1 integrin expression
and exhibited a 2 fold reduction in responsiveness to
these agents when the cells were cultured on
fibronectin. To overcome chemotherapy resistance
from integrin-fibronectin interactions, Nam et al
showed that disrupting the peptide bond between
fibronectin and α5β1-integrin in combination with
radiation therapy promoted apoptosis and reduced
the expression of α5β1 in cultures of malignant human
breast cancer cells cultured atop a 3D Matrigel [5]. The
authors found that the pro-survival effect of
malignant tumor cell α5β1 interaction with fibronectin
in a 3D environment was a result of α5β1 mediated
activation of Akt signaling as Akt kinase and Akt
phosphorylation were downregulated following α5β1
inhibition [5]. Similarly, it was found that primary
glioblastomas resistant to the anti-angiogenic agent
bevacizumab exhibited a higher expression of β1
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integrins and FAK, a phenomenon the authors
attributed to high intra-tumoral hypoxia following
anti-angiogenic therapy [33]. To determine whether
inhibition of β1 integrin improved therapeutic
responses, the authors treated subcutaneously grown
U87MG glioblastomas with alternating doses of a β1
inhibitor and low dose (1mg/kg) bevacizumab [33].
The results showed a significant improvement in
tumor regression in the dual treated animals [33].
These results were comparable to a high dose regimen
(10mg/kg) of bevacizumab alone, suggesting that the
addition of a β1 integrin inhibitor improves the
therapeutic efficiency of bevacizumab [33]. Figure 2
provides a graphical summary of the findings
addressed above. Given these and other similar
studies, it’s apparent that targeting the cellular
interactions with fibronectin and/or fibronectin itself
may be a desirable strategy to improve patient
outcomes.

Figure 2: Integrin-fibronectin interaction in tumor therapy
responses. (A) Tumor cell α5β1 or β1 integrin interaction with fibronectin
results in activation of cell signaling pathways which ultimately culminate in
tumor cell resistance to chemotherapeutic agents. (B) Inhibition of α5β1 or β1
integrin interaction with fibronectin restores tumor cell sensitivity to
chemotherapeutic agents resulting in increased cytotoxicity.

Future Outlook: Potential Strategies for
Targeting Fibronectin
While the aforementioned studies have
provided encouraging evidence to address
therapeutic targets against integrin engagement with
fibronectin, further research is necessary in order to
find novel strategies for inhibiting tumor growth via
targeting fibronectin biosynthesis and/or fibronectin
http://www.jcancer.org
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regulated cell signaling.
Matrix rigidity is a common feature of tumors
and has been shown to support tumor growth,
invasion and metastasis [34]. In response to matrix
rigidity, focal adhesions, complexes of integrin
receptors which facilitate cellular attachments with
the ECM, are formed. FAK, a structural and signaling
component of focal adhesions, has not only been
reported to be upregulated in response to matrix
rigidity [35], but has additionally been shown to
regulate
fibronectin-directed
matrix
fibrillar
organization [36]. For instance, Ilic et al reported that
fibronectin fibrils were more sparse and thinner in
FAK null embryos compared to wildtype littermates
and fibroblasts, a result which was demonstrated to
be independent of fibronectin gene or protein
expression and synthesis, suggesting that FAK
activity is necessary for fibronectin matrix
organization [36]. Interestingly, in a separate study,
fibronectin expression was shown to drive FAK
signaling [29], suggesting that both FAK and
fibronectin may interact in a positive feedback loop.
Given the role of FAK in fibronectin expression, it’s
conceivable that targeting FAK expression may be a
mechanism to reduce fibronectin expression and thus
tumor progression. Meng et al showed that
fibronectin-induced FAK tumor cell migration and
invasion was decreased following treatment of A549
lung tumor cells with the Src inhibitor PP2 [29].
Specifically, the authors reported that inhibition of Src
resulted in decreased FAK phosphorylation
suggesting that a reduction of FAK activity may be a
useful strategy to reduce fibronectin mediated effects
on tumor cell migration and invasion [29]. In addition
to indirect targets of FAK, it may be possible to
directly reduce FAK activity via use of a novel ATP
competitive kinase inhibitor, PF-04554878, which was
recently shown to promote apoptosis and reduce
proliferation of pancreatic neuroendocrine tumor cells
[37].
Aside from targeting FAKs, it may be possible to
directly reduce matrix stiffness in tumors, thereby
preventing FAK-induced fibronectin expression.
Levental et al demonstrated that expression of lysyl
oxidase (LOX), an enzyme which cross-links collagen
fibers [38], not only increased FAK expression, but
augmented matrix rigidity and breast tumor
progression, a phenomenon which was reversed upon
treatment with an inhibitor of LOX [39]. In support of
a role for LOX in fibronectin expression, Adam et al
showed that atrial samples from patients with atrial
fibrillation exhibited increased expression of LOX and
fibronectin [40]. Administration of a small molecule
inhibitor of LOX to neonatal cardiac fibroblasts
attenuated LOX-induced fibronectin expression via
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downregulation of angiotensin II and connective
tissue growth factor [40]. Although this work was
conducted in cardiac fibroblasts, it’s foreseeable that
inhibiting LOX may be a means to reduce tumoral
fibronectin expression. Overall, it is likely that
targeting the molecular machinery which is
responsible for supporting matrix rigidity will reduce
both fibrosis and fibronectin expression and in effect
decrease tumor progression.
While indirect targets against fibronectin should
undoubtedly yield more favorable outcomes for
cancer patients, it would be ideal to directly target the
biosynthesis
of
fibronectin.
To
this
end,
Tomasini-Johansson et al developed a small peptide
inhibitor of fibronectin, pUR4B, which was shown to
limit fibronectin polymerization in the matrix [41].
Work by Chiang et al has shown that administration
of pUR4B in animals which had received a partial
ligation of the external or internal carotid arteries
resulted in reduction of intima, media and adventitial
thickness of the vessels and further decreased the
accumulation of fibronectin and collagen [42].
Furthermore, Hielscher et al demonstrated that
treatment of co-cultures of fibroblasts and breast
cancer cells with pUR4B not only reduced fibronectin
deposition and organization in the ECM, but also
inhibited the deposition of other matrix proteins [43].
Additionally, inhibition of fibronectin matrix
assembly also attenuated vascular morphogenesis of
endothelial
cells
cultured
atop
the
fibronectin-deficient matrix [43]. These studies
illustrate that fibronectin not only serves as a
substrate regulating the assembly of other ECM
proteins but is additionally important for supporting
angiogenesis. As such, direct inhibition of fibronectin
polymerization via a small peptide may impair the
assembly of other matrix proteins and capillaries, thus
depriving tumors of a supportive scaffold and the
oxygen and nutrients necessary for continued growth.
Indeed, the use of such anti-cancer peptides have not
only been used to directly treat cancer but have also
been used as cytotoxic drug carriers [44]. As such, it’s
possible that delivery of a peptide inhibitor of
fibronectin polymerization may be utilized in
conjunction with a chemotherapy regimen to improve
outcomes for cancer patients. A benefit from use of an
inhibitor of fibronectin polymerization is that the off
target effects of the peptide should be minimal as
fibronectin isn’t actively produced in tissues with the
exception of wounds and during development. One
drawback may be concentrating the peptide to
achieve maximal responses. As such, one may need to
complex the inhibitor in a delivery vector to improve
both tumor targeting and sustained delivery of the
peptide at the tumor site.
http://www.jcancer.org

Journal of Cancer 2017, Vol. 8
RNA interference is rapidly becoming a
powerful tool to silence the expression of genes and
has been extensively investigated for its utility as a
form of cancer therapy. Previous studies have shown
that silencing fibronectin reduced tumor cell
proliferation and growth [17] and tumor cell
migration [6]. As such, silencing fibronectin gene
expression via RNA silencing may be an effective
strategy to enhance therapeutic responses. Despite its
obvious advantages, the major drawback associated
with use of gene based therapies is the delivery of
these to the tumor. Traditionally, siRNA have been
delivered locally where they’ve had much success
with regard to treating ocular diseases [45]. For
delivery of fibronectin siRNA to tumors, it will be
important to utilize vectors which not only target the
tumor, but penetrate the tumor cell membrane to
deliver
the
packaged
siRNA
particles.
Cell-penetrating peptides (CPP), which consist of
short peptide sequences of 10-30 amino acids, have
been shown to cross the cellular plasma membrane
[46]. Derived from viral proteins or mammalian
proteins with translocation capabilities, CPPs have
been used to deliver siRNA to in-vitro cell cultures
[47] and in transvascular delivery of siRNA to mice
[48]. Although additional work will be necessary, the
use of these vectors may be an avenue by which to
deliver fibronectin siRNA to tumors.
Another means by which to target fibronectin
expression could come from use of vaccinia viruses,
double stranded DNA viruses used to treat cancer.
Use of vaccinia viruses has received increased interest
as strategies to engineer more potent oncolytic forms
of vaccinia viruses has not only resulted in greater
tumor specificity but have been shown to be an
efficient means by which to lyse tumor cells [49].
Recently, a genetically engineered vaccinia virus was
reported to target both malignant ovarian cancer cells
in addition to the fibroblasts in the tumor stroma [50].
Given that the vaccinia virus was able to infect
fibroblasts, it’s possible that utilizing a similar
strategy may halt the production of fibronectin from
cancer associated fibroblasts as fibroblasts are a
principle cell type responsible for ECM production.
Together, the aforementioned studies have
provided a clearer perspective on the mechanisms
whereby fibronectin exerts its tumorigenic effects in
cancer. These studies suggest that fibronectin is not
only aberrantly expressed in tumors, but also
promotes tumor progression, metastasis and therapy
resistance via activation of a number of downstream
signaling pathways. With advances in this
knowledge, it’s foreseeable that employing strategies
to inhibit tumor cell association with fibronectin,
fibronectin-mediated cell signaling and/or fibronectin
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biosynthesis in the ECM will not only result in
unprecedented discoveries about the mechanisms
fibronectin exerts on tumor cell behavior, but will
additionally result in development of novel
therapeutic approaches to treat cancer.
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